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This multicenter prospective phase II study examines the activity and tolerability of brentuximab vedotin as
second-line therapy in patients with Hodgkin lymphoma that was relapsed or refractory after induction
therapy. Brentuximab vedotin (1.8 mg/kg) was administered i.v. on day 1 of a 21-day cycle for a total of 4
cycles. Patients then proceeded to autologous hematopoietic cell transplantation (AHCT), if eligible, with or
without additional salvage therapy, based on remission status after brentuximab vedotin. The primary
endpoint was overall response rate (ORR). Secondary endpoints were safety, stem cell mobilization/collection,
AHCT outcomes, and association of CD68þ with outcomes. Of 37 patients, the ORR was 68% (13 complete
remission, 12 partial remission). The regimen was well tolerated with few grade 3/4 adverse events, including
lymphopenia (1), neutropenia (3), rash (2), and hyperuricemia (1). Thirty-two patients (86%) were able to
proceed to AHCT, with 24 patients (65%) in complete remission at time of AHCT. Thirteen patients in complete
remission, 4 in partial remission, and 1 with stable disease (49%) received AHCT without salvage combination
chemotherapy. CD68 expression did not correlate with response to brentuximab vedotin. The median number
of stem cells mobilized was 6.0  106 (range, 2.6 to 34), and median number of days to obtain minimum
collection (2  106) was 2 (range, 1 to 6). Brentuximab vedotin as second-line therapy is active, well tolerated,
and allows adequate stem cell collection and engraftment. For Hodgkin lymphoma patients with relapsed/
refractory disease after induction therapy, second-line brentuximab vedotin, followed by combination
chemotherapy for residual disease, can effectively bridge patients to AHCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Up to 30% of patients with Hodgkin lymphoma (HL) will
relapse or are refractory to primary induction chemotherapy
[1,2]. Standard second-line therapies for these patients
include combination chemotherapy regimens such as ICE
(ifosfamide, carboplatin, etoposide), DHAP (dexamethasone,edgments on page 2140.
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ty for Blood and Marrow Transplantation.high dose cytarabine, cisplatin), or GDP (gemcitabine, dexa-
methasone, cisplatin), which typically yield responses rates
of about 60% to 80% but can have signiﬁcant myelosup-
pression, including grade 3/4 thrombocytopenia, febrile
neutropenia, and grade 3/4 anemia. Up to 60% of patients
may require packed RBC transfusion, and 30% may require
platelet transfusion. Combination chemotherapies may also
impair the ability to successfully mobilize stem cells (14%) for
autologous hematopoietic cell transplantation (AHCT) [3-7].
Alternative salvage strategies with fewer hematologic
adverse effects would be advantageous to patients destined
for AHCT.
R. Chen et al. / Biol Blood Marrow Transplant 21 (2015) 2136e2140 2137Brentuximab vedotin is an antibodyedrug conjugate
linking an anti-CD30 antibody to the microtubule-disrupting
agent, monomethyl auristatin E [8]. It selectively induces
apoptosis in CD30-expressing cells while sparing toxicity to
off-target tissues [9]. Based on a phase II trial demonstrating
an overall response rate (ORR) of 75% with a tolerable safety
proﬁle, the US Food and Drug Administration approved
brentuximab vedotin for use in patients with HL who have
received at least 2 prior lines of therapy [10,11]. We expect
that brentuximab vedotin as second-line treatment will also
be efﬁcacious and tolerable. Previously, we demonstrated
that brentuximab vedotin can act as an effective bridge to
allogeneic transplantation [12,13]. We now hypothesize that
brentuximab vedotin as a second-line treatment can be an
effective bridge to autologous transplantation with no dele-
terious effects on stem cell mobilization or engraftment.
METHODS
This is a multicenter, investigator-initiated, phase II clinical trial per-
formed at City of Hope and Weill Cornell Medical College. This trial was
registered with clinicaltrials.gov (NCT01393717) and approved by both
institutional review boards, and an assurance was ﬁled with the US
Department of Health and Human Services. Informed consent was obtained
for all study participants in compliance with the Declaration of Helsinki.
Patient Eligibility
Patients over age 10 years with histologically conﬁrmed CD30þ
relapsed/refractory classical HLwere eligible. All patients had biopsy-proven
relapsed/refractory HL after induction therapy with ABVD (doxorubicin,
bleomycin, vinblastine, dacarbazine), BEACOPP (bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone), or a
combination  consolidative radiotherapy. Pediatric patients may have
received ABVE-PC (doxorubicin, bleomycin, vinblastine, etoposide, predni-
sone, cyclophosphamide). Patients were ineligible if they had received any37 paents enrolled and
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Figure 1. Study schema. Patients with relapsed/refractory HL were treated with b
Radiographic assessment was done at the end of cycle 2 with computed tomography
continue the study if they achieved CR/PR/SD after 2 cycles. Radiographic assessment
went directly to AHCT. Patients who achieved PR had the option of going directly to
indicates local radiation therapy; HDT, high dose therapy.second-line therapy chemotherapy. Patients were required to show radio-
graphically measureable disease and standard organ functions.Treatment Plan
Treatment consisted of 1.8 mg/kg brentuximab vedotin i.v. every
3 weeks for a maximum of 4 cycles. Figure 1 shows the treatment schema.
One cycle of therapy was deﬁned as the 21 days after i.v. administration of
brentuximab vedotin. Patients with complete remission (CR), partial
remission (PR), or stable disease (SD) at the end of 2 cycles were permitted
to continue brentuximab vedotin for 2 more cycles. Patients who achieved
CR or PR were allowed to proceed to AHCT directly. Patients who achieved
PR had the option of receiving additional combination chemotherapy before
AHCT. Patients with SD or progressive disease (PD) were required to un-
dergo salvage chemotherapy before AHCT. The choice of combination
chemotherapy regimen was at the discretion of the treating physician. For
stem cell mobilization most patients received cyclophosphamide (1.5 g/m2)
and granulocyte colony-stimulating factor (G-CSF; 10 mg/kg) as priming
agents, but for slow collectors (<1.0  106 CD34þ cells ﬁrst day) plerixafor
was added per City of Hope standard operating procedures.
Study Design and Statistical Methods
The primary objective was to evaluate the antitumor activity of bren-
tuximab vedotin as second-line therapy. The primary endpoint was the best
ORR (CR plus PR) per 2007 Cheson criteria [14]. Responses were assessed at
end of cycles 2 and 4. All CRs were conﬁrmed by ﬂuorodeoxyglucose posi-
tron emission tomography evaluation with the standardized uptake value
(SUV) to be below the background of the mediastinal blood pool. Secondary
endpoints were toxicity, stem cell mobilization, and engraftment. Based on
historical data with standard chemotherapy regimens, we considered a
response rate of at least 60% to be sufﬁcient to warrant further evaluation. A
Simon 1-stage designwith a 1-sided alpha of 5% and 80% power was used to
assess ORR. In the ﬁrst stage 23 patients were enrolled, with the design
specifying that if 12 or more patients achieved CR or PR, accrual would
continue to a total of 37 patients, with 23 or more responses regarded as
evidence of sufﬁcient activity to warrant further investigation. Toxicity was
assessed every cycle and graded using the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events (CTCAE) version 4.03 [15]. treated with brentuximab 
q 3 wks, up to 4 cycles
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13 CR
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o
AHCT with 
naon chemo
post-chemo
11 CR
18 AHCT without 
combinaon chemo
32 HDT/AHCT
24 CR, 8 PR, 1 SD
Directly to AHCT
4 PR, 1 SD + XRT
rentuximab vedotin 1.8 mg/kg i.v. every 3 weeks for maximum of 4 cycles.
(CT) or CT/positron emission tomography (PET) scan. Patients were allowed to
at the end of the study was done with CT/PET scan. Patients who achieved CR
AHCT or receiving other salvage chemotherapy by investigators choice. XRT
Table 2
Response
Best Response
to Brentuximab
Vedotin
(n ¼ 37)
Response to Combination
Chemotherapy (ICE/DICE/
IGEV/GND) after Brentuximab
Vedotin (n ¼ 18)
Disease Status
at AHCT
(n ¼ 33)
ORR 25/37 (68%) 16/18 (89%)
CR 13/37 (35%) 11/18 (61%) 24/33 (73%)
PR 12/37 (32%) 5/18 (28%) 9/33 (27%)
SD 10/37 (27%) 1/18 (6%) 1/33 (3%)
PD 2/37 (5%) 1/18 (6%)
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Immunohistochemical staining was performed on pretreatment tumor
specimens for CD68; 1.5-mm duplicate cores of diagnostic biopsies of
HL were obtained from representative areas containing Hodgkin Reed-
Sternberg (HRS) cells. The slides were independently scored by Dr. Young
Kim. For CD68 staining, cells were scored in 3 representative high-powered
ﬁelds, and the relative percentage of CD68þ cells in relation to overall
cellularity was reported as previously described [16]. Staining intensity was
then assessed for relationship to response rate.
RESULTS
Efﬁcacy
In total, 37 patients were enrolled in the study between
August 2011 and May 2014. All patients were assessable for
toxicity and efﬁcacy. Table 1 shows baseline patient, disease,
and treatment characteristics. All 37 patients were assessable
for response. The median number of cycles received was 4
(range, 1 to 4). Table 2 details the ORRs. The ORR was 68%
(25/37), with 13 patients attaining CR (35%), 12 patients
attaining PR (32%), 10 patients attaining SD (stable disease,
27%), and 2 patient attaining PD (5%). All patients who ach-
ieved CR did so after 2 cycles of therapy.
When stratiﬁed by stage at diagnosis, the ORRwas 68% for
stage I/II patients (13/19) and 67% for stage III/IV patients
(12/18). When stratiﬁed by response to induction therapy,
the ORR was 67% for primary refractory disease (16/24) and
69% for relapsed disease (9/13). Univariate analysis did not
show signiﬁcant differences in response rates in terms of age,
gender, stage, and response to induction.
Overall, treatment was well tolerated. Table 3 shows all
hematologic adverse events, all grades 3 to 4 adverse events,
and all grades 1 to 2 nonhematologic adverse events occur-
ring in at least 15% of the patients that were at least possibly
related to drug. No patient required growth factor support,
packed RBCs, or platelet transfusions as a of result brentux-
imab vedotin. There were also no neutropenic fevers.
Eighty-six percent of patients (32/37) successfully pro-
ceeded to AHCT. Of the 5 not receiving AHCT, 2 went to
alloHCT and 3 did not respond to second-salvage combina-
tion chemotherapy. Figure 1 shows a ﬂowchart of patient
treatment that includes disease response at each step.
Seventeen of 37 patients received only brentuximab vedotin
(46%) before AHCT. Among the 13 CR patients, all proceeded
to AHCT without additional chemotherapy. Among the 12 PRTable 1
Patient, Disease, and Treatment Characteristics
Characteristics Value
Institution
City of Hope 31 (84%)
Weill Cornell 6 (16%)
Gender
Female 17 (46%)
Male 20 (54%)
Median age, yr (range) 34 (11-67)
Stage at diagnosis
I-II 19 (51%)
III-IV 18 (49%)
Prior radiation therapy 9 (25%)
B symptoms (at diagnosis) 23 (62%)
Bulky disease (5 cm at diagnosis) 32 (86%)
Induction chemotherapy
ABVD 34
ABVD/BEACOPP 2
ABVE-PC 1
Prior radiation therapy 9 (24%)
Best response to induction
Primary refractory 24 (65%)
Relapsed (median 7 months) 13 (35%)patients, 4 proceeded to AHCT without additional chemo-
therapy and 8 received additional salvage chemotherapy
(ICE/DICE/IGEV/GND). All patients with SD/PD received
additional salvage chemotherapy, with the exception of 1
patient who received only local radiation therapy because of
a single site of disease. This patient did not have repeat im-
aging assessment after radiation and thus is counted as a SD.
At the time of AHCT, 24 of 37 patients (65%) were in CR, 7 of
37 (19%) were in PR, and 1 of 37 (3%) was in SD.
All 32 patients who underwent AHCT successfully mobi-
lized stem cells. Twenty-one patients were primed for stem
cell mobilization with cyclophosphamide and G-CSF per
institutional standard of care, and 2 patients received G-CSF
only. Nine patients received plerixafor (per standard oper-
ating procedures). No patient required a second round of
mobilization. The median cell dose collected was 6.0  106
CD34 cells (range, 2.6 to 34). The median number of days
required for collectionwas 2 (range, 1 to 6). Patients received
AHCT conditioning regimens by physician choice, including
BEAM (19/32, BCNU, etoposide, cytarabine, melphalan), CBV
(11/32, cyclophosphamide, BCNU, etoposide), or BEAM plus
yttrium-90 labeled anti-CD25 (2/32). The median time to
neutrophil engraftment (absolute neutrophil count 500 for
3 consecutive days) was 11 days (range 10 to 12) and platelet
engraftment (20,000) 13 days (range, 9 to 23).
Correlative Assays
CD68 expression has been implicated as a poor prognostic
factor in patients undergoing induction chemotherapy [16]
and has also been shown to predict for relapses post-AHCT
[17]. To determine whether CD68 expression is a poorTable 3
Adverse Events
Adverse Events Grade 1 Grade 2 Grade 3 Grade 4
Hematologic
Anemia 16% 3%
Neutropenia 11% 5%
Thrombocytopenia 8%
Lymphopenia 3% 3% 3%
Nonhematologic
Peripheral neuropathy 49% 3%
AST elevation 32% 5% 3%
ALT elevation 27% 11%
Rash (new) 24% 11% 5%
Muscle weakness 24% 5%
Hypoglycemia 22%
Fatigue 19% 11%
Pruritus 19% 3% 3%
Nausea 16% 3%
Abdominal pain 11% 5%
Creatinine elevated 3%
Tumor lysis syndrome 3%
Hyperuricemia 3%
AST indicates aspartate aminotransferase; ALT, alanine aminotransferase.
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vedotin, we performed immunohistochemical staining for
CD68 in our patient samples (City of Hope only) before
brentuximab vedotin treatment. Not surprisingly, all patients
had an intensity score of at least 2 þ because they were all
either relapsed or refractory to induction chemotherapy. A
total of 31% scored as 2þ, 62% as 3þ, and 6% as 4 þ staining
intensity for CD68. Fisher’s exact test was performed to test
for an association between CD68 staining intensity and
response to brentuximab vedotin. In our small sample set, it
does not appear that CD68 staining intensity negatively
impacted the response rates to brentuximab vedotin
(P ¼ .38). We will continue to follow these patients to
determine whether CD68 might be a predictor of relapse
post-AHCT in patients who achieved CR to brentuximab
vedotin as second-line therapy.
DISCUSSION
The ORR of 68% and CR rate of 35% in this study are similar
to the ORR of 75% and CR 34% achieved in the pivotal study of
brentuximab vedotin for HL [10]. The toxicity proﬁle was
mild and similar to that seen in the post-AHCT brentuximab
vedotin trial, with 2 exceptions. Eight percent of patients on
the pivotal trial developed grade 3 peripheral neuropathy,
whereas none of the patients on this trial developed grade
3/4 peripheral neuropathy. This difference may be related to
the brentuximab vedotin 4-dose maximum for patients on
our trial, compared with 16 doses in the post-AHCT trial,
suggesting that peripheral neuropathy from brentuximab
vedotin is a cumulative toxicity. Unlike the pivotal post-AHCT
trial, 40% of our patients developed rashes, with 2 patients
developing grade 3 rashes. The appearance of this toxicity
may be related to the fact that patients in the pivotal trial had
received a median of 3.5 prior therapies, whereas patients in
the current study had only received 1 induction regimen and
were likely better able to mount an immune-mediated skin
reaction to the antibodyedrug conjugate [10]. The results of
our study suggest that brentuximab vedotin has similar ac-
tivity and tolerability when given in the second-line setting
as it has in the setting of post-AHCT failure.
Our results also suggest that brentuximab vedotin as
second-line therapy can effectively bridge patients to AHCT.
Patients in this study received brentuximab vedotin as
second-line therapy, and thosewho achieved a CR proceeded
directly to AHCT. For patients who did not achieve CR,
additional combination salvage chemotherapy such as ICE
was then given to improve the depth of response before
AHCT. This sequential strategy resulted in 13 patients (35%)
in CR immediately after brentuximab vedotin and another 11
patients (30%) in CR after salvage chemotherapy, yielding a
total of 24 patients (65%) in CR at the time of AHCT. This trial
was not designed to replace traditional salvage chemo-
therapywith brentuximab vedotin but rather to demonstrate
that brentuximab vedotin as a second-line therapy can be
safely given before traditional salvage chemotherapy to
bridge patients to AHCT. Granted, the CR rate of 35% achieved
by brentuximab vedotin is lower than the 60% positron
emission tomography CR rate seen for ICE [4]. However, the
CR rate of multiagent chemotherapy given as third-line
therapy is 61% (11/18), suggesting that delaying multiagent
chemotherapy does not have a deleterious effect on efﬁcacy.
It is also important to note that 18 patients (49%) pro-
ceeded directly to AHCT without multiagent salvage
chemotherapy. The toxicity proﬁle for brentuximab vedotin
in this trial was milder than that seen for historical controlsubjects for salvage chemotherapy regimens. Toxicities such
as neutropenia, thrombocytopenia, anemia, fever, nausea,
vomiting, and mucositis are fairly common in multiagent
salvage chemotherapy [3-5]. The initial ICE study resulted in
13% grade 4 neutropenia requiring hospitalization and a 14%
stem cell mobilization failure rate [6]. It is important to note
that none of the patients in this trial required growth factor
support or blood product transfusions as a result of bren-
tuximab vedotin administration. There were also no stem
cell mobilization failures in our patients. Brentuximab
vedotin did not decrease the median number of stem cells
collected or prolong the median number of days required to
reach the minimum collection target. The absolute neutro-
phil count and platelet engraftment times were also similar
to historical control subjects. All but 4 patients were able to
proceed to AHCT, demonstrating that delaying combination
salvage chemotherapy did not negatively impact bridging
patients to AHCT.
This study was not designed to predict how this bridging
strategy will affect long-term outcomes after AHCT. As sec-
ondary endpoints, we continue collecting toxicity proﬁle data
and progression-free survival, overall, and relapse rates.
However, follow-up is too short for us todrawanyconclusions
at this point.Wedoknowfrompriorpublications that thebest
predictor of outcomes for HL patients post-AHCT is CR status
before AHCT [4]. Moskowitz et al. [18] recently published a
similar trial using weekly brentuximab vedotin followed by
augmented ICE before AHCT. They showed that sequential
salvage therapy with brentuximab vedotin followed by
augmented ICE resulted in a higher proportion of patients
achieving CR at the time of AHCT than historically seen for ICE
alone. They observed a 2-year event-free survival of 80% after
the sequential strategy. Although longer follow-up is needed
to determine the survival outcomes of the patients who
received AHCT after our sequential strategy, our current re-
sults are consistent with the Moskowitz study and support
the use of sequential brentuximab vedotin salvage therapy
followed by combination chemotherapy before AHCT.
Although the results of this trial support the Moskowitz
study in terms of bridging patients to AHCT, there are several
differences. First, our brentuximab vedotin dosing schedule
was 1.8 mg/kg once every 3 weeks, whereas Moskowitz et al.
used 1.2 mg/kg once weekly dosing. Second, we let the in-
dividual physician choose the multiagent salvage chemo-
therapy regimen, given that this was a multicenter study and
there are no data on superiority of any 1 particular multi-
agent chemotherapy regimen. Third, we allowed patients
who were in PR after brentuximab vedotin to proceed
directly to AHCT without additional therapy, and 4 patients
in our trial were transplanted in PR. Although evidence
shows improved post-AHCT outcomes for patients in CR at
the time of AHCT, there is no guarantee that CR can be ach-
ieved with additional therapy before AHCT. Last but not least,
we performed rapid restaging after the ﬁrst 2 doses of
brentuximab vedotin. All patients who achieved CR did so by
cycle 2, and further dosing with 2 additional cycles did not
convert any patients from PR to CR. In the initial pivotal trial,
many patients who achieved PR eventually developed PD
while still on therapy. Interestingly, 3 of our patients ach-
ieved PR by cycle 2 and developed PD later, suggesting that
resistance to brentuximab vedotin can develop even after a
short exposure. Based on the results of the study presented
here, we would recommend giving additional multiagent
chemotherapy for patients not in CR after 2 cycles of bren-
tuximab vedotin.
R. Chen et al. / Biol Blood Marrow Transplant 21 (2015) 2136e21402140CD68 expression has been implicated as a poor prognostic
factor in patients undergoing induction chemotherapy [16]
and is also shown to predict for relapse post-AHCT [17].
Although our sample size is small, our data suggest that in-
tensity of CD68 expression did not negatively impact
response rates to brentuximab vedotin, at least in the context
of a cohort where all patients exhibit at least 2 þ staining for
CD68. We are currently assessing the expression of drug
exporters in our tumor samples, because this class of mole-
cules has been associated with resistance to antimicrotubule
agents in other tumor types [17,19,20].
This study demonstrated that brentuximab vedotin as
second-line therapy for patients with HL is active, well
tolerated, and does not hinder stem cell collection or
engraftment. Eighty-six percent of the patients were effec-
tively bridged to AHCT, 49% of which were sparedmultiagent
salvage chemotherapy. This toxicity sparing is particularly
important for a patient population that is younger and has
many years to live with their treatment toxicities. For HL
patients with relapsed/refractory disease after induction
chemotherapy, brentuximab vedotin as second-line therapy
followed by combination chemotherapy before AHCT can be
considered a viable approach.
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